Listed

Anixa Biosciences Inc

ANIXNasdaqCIK 715446HealthcareFiscal year ends Oct 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$0, Q4 FY2023
Operating income−$2.7m, Q3 FY2026
Net income−$2.6m, Q3 FY2026
Anixa Biosciences Inc, income statement, quarterly
Line itemUnitQ4 FY20232023-10-31Q1 FY20242024-01-31Q2 FY20242024-04-30Q3 FY20242024-07-31Q4 FY20242024-10-31Q1 FY20252025-01-31Q2 FY20252025-04-30Q3 FY20252025-07-31Q4 FY20252025-10-31Q1 FY20262026-01-31Q2 FY20262026-04-30Q3 FY20262026-07-31
Revenue$k0.0Revenue, Q4 FY2023, three months to 2023-10-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-01-10, accession 0001493152-25-001787. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Cost of revenue$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Research and development$k1,615Research and development, Q4 FY2023, three months to 2023-10-31$1.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-01-10, accession 0001493152-25-001787. Derived: 12-month figure less the 9-month figure.Report this figure1,349Research and development, Q1 FY2024, three months to 2024-01-31$1.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-03-11, accession 0001493152-25-009854.Report this figure1,646Research and development, Q2 FY2024, three months to 2024-04-30$1.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-28, accession 0001641172-25-012701.Report this figure1,925Research and development, Q3 FY2024, three months to 2024-07-31$1.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-09-10, accession 0001493152-25-013000.Report this figure1,476Research and development, Q4 FY2024, three months to 2024-10-31$1.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-01-12, accession 0001493152-26-001845. Derived: 12-month figure less the 9-month figure.Report this figure1,552Research and development, Q1 FY2025, three months to 2025-01-31$1.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-03-09, accession 0001493152-26-009370.Report this figure1,322Research and development, Q2 FY2025, three months to 2025-04-30$1.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-06-10, accession 0001493152-26-028105.Report this figure1,055Research and development, Q3 FY2025, three months to 2025-07-31$1.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-09-09, accession 0001493152-26-041963.Report this figure1,142Research and development, Q4 FY2025, three months to 2025-10-31$1.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-01-12, accession 0001493152-26-001845. Derived: 12-month figure less the 9-month figure.Report this figure1,102Research and development, Q1 FY2026, three months to 2026-01-31$1.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-03-09, accession 0001493152-26-009370.Report this figure1,258Research and development, Q2 FY2026, three months to 2026-04-30$1.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-06-10, accession 0001493152-26-028105.Report this figure1,326Research and development, Q3 FY2026, three months to 2026-07-31$1.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-09-09, accession 0001493152-26-041963.Report this figure
Selling, general and administrative$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Operating income$k(3,051)Operating income, Q4 FY2023, three months to 2023-10-31−$3.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-01-10, accession 0001493152-25-001787. Derived: 12-month figure less the 9-month figure.Report this figure(3,609)Operating income, Q1 FY2024, three months to 2024-01-31−$3.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-03-11, accession 0001493152-25-009854.Report this figure(3,467)Operating income, Q2 FY2024, three months to 2024-04-30−$3.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-28, accession 0001641172-25-012701.Report this figure(3,592)Operating income, Q3 FY2024, three months to 2024-07-31−$3.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-09-10, accession 0001493152-25-013000.Report this figure(3,163)Operating income, Q4 FY2024, three months to 2024-10-31−$3.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-01-12, accession 0001493152-26-001845. Derived: 12-month figure less the 9-month figure.Report this figure(3,386)Operating income, Q1 FY2025, three months to 2025-01-31−$3.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-03-09, accession 0001493152-26-009370.Report this figure(3,003)Operating income, Q2 FY2025, three months to 2025-04-30−$3.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-06-10, accession 0001493152-26-028105.Report this figure(2,436)Operating income, Q3 FY2025, three months to 2025-07-31−$2.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-09-09, accession 0001493152-26-041963.Report this figure(2,876)Operating income, Q4 FY2025, three months to 2025-10-31−$2.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-01-12, accession 0001493152-26-001845. Derived: 12-month figure less the 9-month figure.Report this figure(2,716)Operating income, Q1 FY2026, three months to 2026-01-31−$2.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-03-09, accession 0001493152-26-009370.Report this figure(2,647)Operating income, Q2 FY2026, three months to 2026-04-30−$2.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-06-10, accession 0001493152-26-028105.Report this figure(2,737)Operating income, Q3 FY2026, three months to 2026-07-31−$2.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-09-09, accession 0001493152-26-041963.Report this figure
Interest expense$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Income tax$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Net income$k(2,690)Net income, Q4 FY2023, three months to 2023-10-31−$2.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-01-10, accession 0001493152-25-001787. Derived: 12-month figure less the 9-month figure.Report this figure(3,255)Net income, Q1 FY2024, three months to 2024-01-31−$3.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-03-11, accession 0001493152-25-009854.Report this figure(3,139)Net income, Q2 FY2024, three months to 2024-04-30−$3.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-05-28, accession 0001641172-25-012701.Report this figure(3,277)Net income, Q3 FY2024, three months to 2024-07-31−$3.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-09-10, accession 0001493152-25-013000.Report this figure(2,883)Net income, Q4 FY2024, three months to 2024-10-31−$2.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-01-12, accession 0001493152-26-001845. Derived: 12-month figure less the 9-month figure.Report this figure(3,184)Net income, Q1 FY2025, three months to 2025-01-31−$3.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-03-09, accession 0001493152-26-009370.Report this figure(2,790)Net income, Q2 FY2025, three months to 2025-04-30−$2.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-06-10, accession 0001493152-26-028105.Report this figure(2,258)Net income, Q3 FY2025, three months to 2025-07-31−$2.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-09-09, accession 0001493152-26-041963.Report this figure(2,695)Net income, Q4 FY2025, three months to 2025-10-31−$2.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-01-12, accession 0001493152-26-001845. Derived: 12-month figure less the 9-month figure.Report this figure(2,565)Net income, Q1 FY2026, three months to 2026-01-31−$2.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-03-09, accession 0001493152-26-009370.Report this figure(2,516)Net income, Q2 FY2026, three months to 2026-04-30−$2.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-06-10, accession 0001493152-26-028105.Report this figure(2,606)Net income, Q3 FY2026, three months to 2026-07-31−$2.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-09-09, accession 0001493152-26-041963.Report this figure
Diluted EPS$ per sharenot reported(0.10)Diluted EPS, Q1 FY2024, three months to 2024-01-31−$0.10 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-03-11, accession 0001493152-25-009854.Report this figure(0.10)Diluted EPS, Q2 FY2024, three months to 2024-04-30−$0.10 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-28, accession 0001641172-25-012701.Report this figure(0.10)Diluted EPS, Q3 FY2024, three months to 2024-07-31−$0.10 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-09-10, accession 0001493152-25-013000.Report this figurenot reported(0.10)Diluted EPS, Q1 FY2025, three months to 2025-01-31−$0.10 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-03-09, accession 0001493152-26-009370.Report this figure(0.09)Diluted EPS, Q2 FY2025, three months to 2025-04-30−$0.09 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-06-10, accession 0001493152-26-028105.Report this figure(0.07)Diluted EPS, Q3 FY2025, three months to 2025-07-31−$0.07 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-09-09, accession 0001493152-26-041963.Report this figurenot reported(0.08)Diluted EPS, Q1 FY2026, three months to 2026-01-31−$0.08 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-03-09, accession 0001493152-26-009370.Report this figure(0.07)Diluted EPS, Q2 FY2026, three months to 2026-04-30−$0.07 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-06-10, accession 0001493152-26-028105.Report this figure(0.08)Diluted EPS, Q3 FY2026, three months to 2026-07-31−$0.08 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-09-09, accession 0001493152-26-041963.Report this figure
Basic EPS$ per sharenot reported(0.10)Basic EPS, Q1 FY2024, three months to 2024-01-31−$0.10 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-03-11, accession 0001493152-25-009854.Report this figure(0.10)Basic EPS, Q2 FY2024, three months to 2024-04-30−$0.10 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-28, accession 0001641172-25-012701.Report this figure(0.10)Basic EPS, Q3 FY2024, three months to 2024-07-31−$0.10 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-09-10, accession 0001493152-25-013000.Report this figurenot reported(0.10)Basic EPS, Q1 FY2025, three months to 2025-01-31−$0.10 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-03-09, accession 0001493152-26-009370.Report this figure(0.09)Basic EPS, Q2 FY2025, three months to 2025-04-30−$0.09 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-06-10, accession 0001493152-26-028105.Report this figure(0.07)Basic EPS, Q3 FY2025, three months to 2025-07-31−$0.07 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-09-09, accession 0001493152-26-041963.Report this figurenot reported(0.08)Basic EPS, Q1 FY2026, three months to 2026-01-31−$0.08 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-03-09, accession 0001493152-26-009370.Report this figure(0.07)Basic EPS, Q2 FY2026, three months to 2026-04-30−$0.07 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-06-10, accession 0001493152-26-028105.Report this figure(0.08)Basic EPS, Q3 FY2026, three months to 2026-07-31−$0.08 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-09-09, accession 0001493152-26-041963.Report this figure

Balance sheet

Cash and equivalents$1.4m, Q3 FY2026
Shareholders' equity$14.5m, Q3 FY2026
Anixa Biosciences Inc, balance sheet, quarterly
Line itemUnitFY20232023-10-31Q1 FY20242024-01-31Q2 FY20242024-04-30Q3 FY20242024-07-31FY20242024-10-31Q1 FY20252025-01-31Q2 FY20252025-04-30Q3 FY20252025-07-31FY20252025-10-31Q1 FY20262026-01-31Q2 FY20262026-04-30Q3 FY20262026-07-31
Cash and equivalents$m0.9Cash and equivalents, FY2023, at 2023-10-31$915.0k. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-01-10, accession 0001493152-25-001787.Report this figure1.0Cash and equivalents, Q1 FY2024, at 2024-01-31$998.0k. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-03-12, accession 0001493152-24-009683.Report this figure1.0Cash and equivalents, Q2 FY2024, at 2024-04-30$995.0k. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-06-04, accession 0001493152-24-022573.Report this figure1.2Cash and equivalents, Q3 FY2024, at 2024-07-31$1.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-09-06, accession 0001493152-24-035335.Report this figure1.3Cash and equivalents, FY2024, at 2024-10-31$1.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-01-12, accession 0001493152-26-001845.Report this figure1.1Cash and equivalents, Q1 FY2025, at 2025-01-31$1.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-03-11, accession 0001493152-25-009854.Report this figure1.9Cash and equivalents, Q2 FY2025, at 2025-04-30$1.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-28, accession 0001641172-25-012701.Report this figure1.5Cash and equivalents, Q3 FY2025, at 2025-07-31$1.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-09-10, accession 0001493152-25-013000.Report this figure1.2Cash and equivalents, FY2025, at 2025-10-31$1.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-09-09, accession 0001493152-26-041963.Report this figure1.5Cash and equivalents, Q1 FY2026, at 2026-01-31$1.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-03-09, accession 0001493152-26-009370.Report this figure1.5Cash and equivalents, Q2 FY2026, at 2026-04-30$1.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-06-10, accession 0001493152-26-028105.Report this figure1.4Cash and equivalents, Q3 FY2026, at 2026-07-31$1.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-09-09, accession 0001493152-26-041963.Report this figure
Current assets$m25.4Current assets, FY2023, at 2023-10-31$25.4m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-01-10, accession 0001493152-25-001787.Report this figure25.2Current assets, Q1 FY2024, at 2024-01-31$25.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-03-12, accession 0001493152-24-009683.Report this figure24.2Current assets, Q2 FY2024, at 2024-04-30$24.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-06-04, accession 0001493152-24-022573.Report this figure22.7Current assets, Q3 FY2024, at 2024-07-31$22.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-09-06, accession 0001493152-24-035335.Report this figure21.4Current assets, FY2024, at 2024-10-31$21.4m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-01-12, accession 0001493152-26-001845.Report this figure18.7Current assets, Q1 FY2025, at 2025-01-31$18.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-03-11, accession 0001493152-25-009854.Report this figure16.8Current assets, Q2 FY2025, at 2025-04-30$16.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-28, accession 0001641172-25-012701.Report this figure17.4Current assets, Q3 FY2025, at 2025-07-31$17.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-09-10, accession 0001493152-25-013000.Report this figure15.9Current assets, FY2025, at 2025-10-31$15.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-09-09, accession 0001493152-26-041963.Report this figure15.1Current assets, Q1 FY2026, at 2026-01-31$15.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-03-09, accession 0001493152-26-009370.Report this figure14.7Current assets, Q2 FY2026, at 2026-04-30$14.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-06-10, accession 0001493152-26-028105.Report this figure14.9Current assets, Q3 FY2026, at 2026-07-31$14.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-09-09, accession 0001493152-26-041963.Report this figure
Total assets$m25.5Total assets, FY2023, at 2023-10-31$25.5m. XBRL concept us-gaap:Assets. 10-K filed 2025-01-10, accession 0001493152-25-001787.Report this figure25.4Total assets, Q1 FY2024, at 2024-01-31$25.4m. XBRL concept us-gaap:Assets. 10-Q filed 2024-03-12, accession 0001493152-24-009683.Report this figure24.4Total assets, Q2 FY2024, at 2024-04-30$24.4m. XBRL concept us-gaap:Assets. 10-Q filed 2024-06-04, accession 0001493152-24-022573.Report this figure22.9Total assets, Q3 FY2024, at 2024-07-31$22.9m. XBRL concept us-gaap:Assets. 10-Q filed 2024-09-06, accession 0001493152-24-035335.Report this figure21.6Total assets, FY2024, at 2024-10-31$21.6m. XBRL concept us-gaap:Assets. 10-K filed 2026-01-12, accession 0001493152-26-001845.Report this figure18.9Total assets, Q1 FY2025, at 2025-01-31$18.9m. XBRL concept us-gaap:Assets. 10-Q filed 2025-03-11, accession 0001493152-25-009854.Report this figure17.0Total assets, Q2 FY2025, at 2025-04-30$17.0m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-28, accession 0001641172-25-012701.Report this figure17.7Total assets, Q3 FY2025, at 2025-07-31$17.7m. XBRL concept us-gaap:Assets. 10-Q filed 2025-09-10, accession 0001493152-25-013000.Report this figure16.1Total assets, FY2025, at 2025-10-31$16.1m. XBRL concept us-gaap:Assets. 10-Q filed 2026-09-09, accession 0001493152-26-041963.Report this figure15.2Total assets, Q1 FY2026, at 2026-01-31$15.2m. XBRL concept us-gaap:Assets. 10-Q filed 2026-03-09, accession 0001493152-26-009370.Report this figure14.9Total assets, Q2 FY2026, at 2026-04-30$14.9m. XBRL concept us-gaap:Assets. 10-Q filed 2026-06-10, accession 0001493152-26-028105.Report this figure15.1Total assets, Q3 FY2026, at 2026-07-31$15.1m. XBRL concept us-gaap:Assets. 10-Q filed 2026-09-09, accession 0001493152-26-041963.Report this figure
Current liabilities$m2.0Current liabilities, FY2023, at 2023-10-31$2.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-01-10, accession 0001493152-25-001787.Report this figure1.7Current liabilities, Q1 FY2024, at 2024-01-31$1.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-03-12, accession 0001493152-24-009683.Report this figure1.7Current liabilities, Q2 FY2024, at 2024-04-30$1.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-06-04, accession 0001493152-24-022573.Report this figure2.0Current liabilities, Q3 FY2024, at 2024-07-31$2.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-09-06, accession 0001493152-24-035335.Report this figure2.5Current liabilities, FY2024, at 2024-10-31$2.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-01-12, accession 0001493152-26-001845.Report this figure2.0Current liabilities, Q1 FY2025, at 2025-01-31$2.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-03-11, accession 0001493152-25-009854.Report this figure1.9Current liabilities, Q2 FY2025, at 2025-04-30$1.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-28, accession 0001641172-25-012701.Report this figure2.1Current liabilities, Q3 FY2025, at 2025-07-31$2.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-09-10, accession 0001493152-25-013000.Report this figure2.0Current liabilities, FY2025, at 2025-10-31$2.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-09-09, accession 0001493152-26-041963.Report this figure1.2Current liabilities, Q1 FY2026, at 2026-01-31$1.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-03-09, accession 0001493152-26-009370.Report this figure1.5Current liabilities, Q2 FY2026, at 2026-04-30$1.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-06-10, accession 0001493152-26-028105.Report this figure1.7Current liabilities, Q3 FY2026, at 2026-07-31$1.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-09-09, accession 0001493152-26-041963.Report this figure
Total liabilities$m2.2Total liabilities, FY2023, at 2023-10-31$2.2m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-01-10, accession 0001493152-25-001787.Report this figure1.8Total liabilities, Q1 FY2024, at 2024-01-31$1.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-03-12, accession 0001493152-24-009683.Report this figure1.8Total liabilities, Q2 FY2024, at 2024-04-30$1.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-06-04, accession 0001493152-24-022573.Report this figure2.2Total liabilities, Q3 FY2024, at 2024-07-31$2.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-09-06, accession 0001493152-24-035335.Report this figure2.7Total liabilities, FY2024, at 2024-10-31$2.7m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-01-12, accession 0001493152-26-001845.Report this figure2.2Total liabilities, Q1 FY2025, at 2025-01-31$2.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-03-11, accession 0001493152-25-009854.Report this figure2.1Total liabilities, Q2 FY2025, at 2025-04-30$2.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-28, accession 0001641172-25-012701.Report this figure2.2Total liabilities, Q3 FY2025, at 2025-07-31$2.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-09-10, accession 0001493152-25-013000.Report this figure2.1Total liabilities, FY2025, at 2025-10-31$2.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-09-09, accession 0001493152-26-041963.Report this figure1.4Total liabilities, Q1 FY2026, at 2026-01-31$1.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-03-09, accession 0001493152-26-009370.Report this figure1.6Total liabilities, Q2 FY2026, at 2026-04-30$1.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-06-10, accession 0001493152-26-028105.Report this figure1.9Total liabilities, Q3 FY2026, at 2026-07-31$1.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-09-09, accession 0001493152-26-041963.Report this figure
Long-term debt$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Shareholders' equity$m24.3Shareholders' equity, FY2023, at 2023-10-31$24.3m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2025-01-10, accession 0001493152-25-001787.Report this figure24.6Shareholders' equity, Q1 FY2024, at 2024-01-31$24.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-03-12, accession 0001493152-24-009683.Report this figure23.6Shareholders' equity, Q2 FY2024, at 2024-04-30$23.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-06-04, accession 0001493152-24-022573.Report this figure21.8Shareholders' equity, Q3 FY2024, at 2024-07-31$21.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-09-06, accession 0001493152-24-035335.Report this figure20.0Shareholders' equity, FY2024, at 2024-10-31$20.0m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-01-12, accession 0001493152-26-001845.Report this figure17.9Shareholders' equity, Q1 FY2025, at 2025-01-31$17.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-03-11, accession 0001493152-25-009854.Report this figure16.1Shareholders' equity, Q2 FY2025, at 2025-04-30$16.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-05-28, accession 0001641172-25-012701.Report this figure16.6Shareholders' equity, Q3 FY2025, at 2025-07-31$16.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-09-10, accession 0001493152-25-013000.Report this figure15.2Shareholders' equity, FY2025, at 2025-10-31$15.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-09-09, accession 0001493152-26-041963.Report this figure15.1Shareholders' equity, Q1 FY2026, at 2026-01-31$15.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-03-09, accession 0001493152-26-009370.Report this figure14.5Shareholders' equity, Q2 FY2026, at 2026-04-30$14.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-06-10, accession 0001493152-26-028105.Report this figure14.5Shareholders' equity, Q3 FY2026, at 2026-07-31$14.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-09-09, accession 0001493152-26-041963.Report this figure

Cash flow

Operating cash flow−$1.8m, Q3 FY2026
Anixa Biosciences Inc, cash flow, quarterly
Line itemUnitQ4 FY20232023-10-31Q1 FY20242024-01-31Q2 FY20242024-04-30Q3 FY20242024-07-31Q4 FY20242024-10-31Q1 FY20252025-01-31Q2 FY20252025-04-30Q3 FY20252025-07-31Q4 FY20252025-10-31Q1 FY20262026-01-31Q2 FY20262026-04-30Q3 FY20262026-07-31
Operating cash flow$k(1,969)Operating cash flow, Q4 FY2023, three months to 2023-10-31−$2.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-01-10, accession 0001493152-25-001787. Derived: 12-month figure less the 9-month figure.Report this figure(2,309)Operating cash flow, Q1 FY2024, three months to 2024-01-31−$2.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-03-11, accession 0001493152-25-009854.Report this figure(1,456)Operating cash flow, Q2 FY2024, three months to 2024-04-30−$1.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-28, accession 0001641172-25-012701. Derived: 6-month figure less the 3-month figure.Report this figure(2,643)Operating cash flow, Q3 FY2024, three months to 2024-07-31−$2.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-09-10, accession 0001493152-25-013000. Derived: 9-month figure less the 6-month figure.Report this figure(927)Operating cash flow, Q4 FY2024, three months to 2024-10-31−$927.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-01-12, accession 0001493152-26-001845. Derived: 12-month figure less the 9-month figure.Report this figure(2,904)Operating cash flow, Q1 FY2025, three months to 2025-01-31−$2.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-03-09, accession 0001493152-26-009370.Report this figure(1,503)Operating cash flow, Q2 FY2025, three months to 2025-04-30−$1.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-06-10, accession 0001493152-26-028105. Derived: 6-month figure less the 3-month figure.Report this figure(1,511)Operating cash flow, Q3 FY2025, three months to 2025-07-31−$1.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-09-09, accession 0001493152-26-041963. Derived: 9-month figure less the 6-month figure.Report this figure(1,255)Operating cash flow, Q4 FY2025, three months to 2025-10-31−$1.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-01-12, accession 0001493152-26-001845. Derived: 12-month figure less the 9-month figure.Report this figure(2,610)Operating cash flow, Q1 FY2026, three months to 2026-01-31−$2.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-03-09, accession 0001493152-26-009370.Report this figure(1,741)Operating cash flow, Q2 FY2026, three months to 2026-04-30−$1.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-06-10, accession 0001493152-26-028105. Derived: 6-month figure less the 3-month figure.Report this figure(1,770)Operating cash flow, Q3 FY2026, three months to 2026-07-31−$1.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-09-09, accession 0001493152-26-041963. Derived: 9-month figure less the 6-month figure.Report this figure
Capital expenditure$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported

Shares

Diluted shares (weighted)34.18m, Q3 FY2026
Anixa Biosciences Inc, shares, quarterly
Line itemUnitQ1 FY20232023-01-31Q2 FY20232023-04-30Q3 FY20232023-07-31Q1 FY20242024-01-31Q2 FY20242024-04-30Q3 FY20242024-07-31Q1 FY20252025-01-31Q2 FY20252025-04-30Q3 FY20252025-07-31Q1 FY20262026-01-31Q2 FY20262026-04-30Q3 FY20262026-07-31
Diluted shares (weighted)m shares0.0Diluted shares (weighted), Q1 FY2023, three months to 2023-01-3130,921 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-03-12, accession 0001493152-24-009683.Report this figure0.0Diluted shares (weighted), Q2 FY2023, three months to 2023-04-3030,930 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-06-04, accession 0001493152-24-022573.Report this figure0.0Diluted shares (weighted), Q3 FY2023, three months to 2023-07-3130,974 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-09-06, accession 0001493152-24-035335.Report this figure31.4Diluted shares (weighted), Q1 FY2024, three months to 2024-01-3131,446,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-03-11, accession 0001493152-25-009854.Report this figure31.9Diluted shares (weighted), Q2 FY2024, three months to 2024-04-3031,914,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-28, accession 0001641172-25-012701.Report this figure32.1Diluted shares (weighted), Q3 FY2024, three months to 2024-07-3132,054,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-09-10, accession 0001493152-25-013000.Report this figure32.2Diluted shares (weighted), Q1 FY2025, three months to 2025-01-3132,197,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-03-09, accession 0001493152-26-009370.Report this figure32.2Diluted shares (weighted), Q2 FY2025, three months to 2025-04-3032,202,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-06-10, accession 0001493152-26-028105.Report this figure32.5Diluted shares (weighted), Q3 FY2025, three months to 2025-07-3132,476,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-09-09, accession 0001493152-26-041963.Report this figure33.2Diluted shares (weighted), Q1 FY2026, three months to 2026-01-3133,240,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-03-09, accession 0001493152-26-009370.Report this figure33.6Diluted shares (weighted), Q2 FY2026, three months to 2026-04-3033,593,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-06-10, accession 0001493152-26-028105.Report this figure34.2Diluted shares (weighted), Q3 FY2026, three months to 2026-07-3134,182,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-09-09, accession 0001493152-26-041963.Report this figure

Shares outstanding: 34.76mShares outstanding, period not labelled, at 2026-09-0934,763,802 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-09-09, accession 0001493152-26-041963.Report this figure at Sep 9, 2026, from the cover of the 10-Q filed Sep 9, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:22 ET. Listed shows no prices and gives no investment advice.